natgillin/translations-raw huggingface dataset:
cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants), - alfentanil, fentanyl (used to treat pain), - quinidine (used to treat an irregular heart beat), - irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer), - medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines), - warfarin, acenocoumarol (blood thinners; blood tests may be required), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections) - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - nefazodone (used to treat depression), - corticosteroids (such as dexamethasone and methylprednisolone), - anti-anxiety medicines (such as alprazolam), - tolbutamide (a medicine used to treat diabetes) 
- ciklosporin, takrolimus, sirolimus, everolimus (za zaviranje imunske odzivnosti), - alfentanil, fentanil (za zdravljenje bolečine), - kinidin (za zdravljenje nepravilnega srčnega utripa), - irinotekan, etopozid, vinorelbin, ifosfamid (zdravila za zdravljenje raka), - zdravila, ki vsebujejo derivate ergot alkaloidov, kot sta ergotamin in diergotamin (za zdravljenje migrene), - varfarin, acenokumarol (za redčenje krvi; mogoče bo treba narediti krvne teste), - rifampicin, klaritromicin, telitromicin (antibiotiki za zdravljenje okužb), - fenitoin (zdravilo za zdravljenje epileptičnih krčev/napadov), - karbamazepin (za zdravljenje depresije in epilepsije), - midazolam, triazolam, fenobarbital (zdravila za pomirjanje in lažje spanje), - šentjanževka (rastlinski pripravek za zdravljenje depresije), - zaviralci proteaz (za zdravljenje okužbe s HIV), - ketokonazol - razen šampona (za zdravljenje Cushingovega sindroma - če v telesu nastaja preveč kortizola), - itrakonazol, vorikonazol, posakonazol (za zdravljenje glivičnih okužb), - nefazodon (za zdravljenje depresije), - kortikosteroidi (kot sta deksametazon in metilprednizolon), - zdravila proti strahu, tesnobi (kot je alprazolam), - tolbutamid (za zdravljenje sladkorne bolezni).
The 125 mg capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body. 
125 mg kapsule so neprozorne; telo je bele barve, pokrovček je rožnate barve; na telesu kapsule sta radialno s črnim črnilom natisnjeni oznaki "462" in "125 mg".
The effects of EMEND or other medicines might be influenced if you or the child take EMEND together with other medicines including those listed below. 
Če vi ali otrok jemljete zdravilo EMEND skupaj z drugimi zdravili, vključno s spodaj naštetimi, to lahko vpliva na učinek zdravila EMEND ali teh zdravil.
It is anticipated that EMEND 165 mg would cause similar induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6 to 8 days after first aprepitant dose has been observed. 
Uporaba enkratnega odmerka aprepitanta 200 mg 1. dan skupaj z midazolamom, občutljivim substratom CYP3A4, prvi, 4. in 8. dan je povzročila 35 % zmanjšanje vrednosti AUC0- midazolama 8. dan. Pričakujemo, da zdravilo EMEND 165 mg povzroči podobno indukcijo CYP2C9, CYP3A4 in glukuronidacije kot 3-dnevna shema s peroralnim aprepitantom, pri kateri so opazili prehodno indukcijo z največjim učinkim 6 do 8 dni po prvem odmerku aprepitanta.
Uncommon: may affect up to 1 in 100 people - feeling dizzy or sleepy - acne, rash - feeling anxious - burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind - pain or burning when urinating - feeling weak, generally feeling unwell - hot flushes/reddening of the face or skin - fast or irregular heart beat - fever with increased risk of infection, low number of red blood cells (shown in tests). 
Občasni: pojavijo se lahko pri do 1 od 100 bolnikov - omotica ali zaspanost - akne, izpuščaj - občutek tesnobe - spahovanje, siljenje na bruhanje, bruhanje, zgaga, bolečine v trebuhu, suha usta, vetrovi - bolečina ali pekoč občutek pri uriniranju - občutek šibkosti, splošno slabo počutje - vročinski oblivi/pordelost obraza ali kože - hiter ali nepravilen srčni utrip - zvišana telesna temperatura s povečanim tveganjem za okužbo, nizko število rdečih krvnih celic
Aluminium blister containing one 80 mg capsule. 
Aluminijast pretisni omot, ki vsebuje eno 80 mg kapsulo.
See the product information for the selected 5-HT3 antagonist for the appropriate dosing information 
Za ustrezne informacije o odmerjanju glejte informacije o zdravilu za izbrani antagonist 5-HT3.
5 Aluminium blisters each containing one 125 mg capsule. 
Pet aluminijastih pretisnih omotov, ki vsebujejo po eno 125 mg kapsulo.
The aprepitant regimen for children aged 6 months to less than 12 years (n=105) consisted of EMEND powder for oral suspension 3.0 mg/kg (up to 125 mg) orally on Day 1 and 2.0 mg/kg (up to 80 mg) orally on Days 2 and 3 in combination with ondansetron on Day 1. 
Shema z aprepitantom je za mladostnike, stare od 12 do 17 let (n = 47), obsegala 125 mg kapsulo zdravila EMEND peroralno 1. dan in 80 mg/dan 2. in 3. dan v kombinaciji z ondansetronom 1. dan. Shema z aprepitantom za otroke, stare od 6 mesecev do manj kot 12 let (n = 105), je obsegala 3,0 mg/kg (do 125 mg) zdravila EMEND v prašku za peroralno suspenzijo peroralno 1. dan in 2,0 mg/kg (do 80 mg) peroralno na 2. in 3. dan v kombinaciji z ondansetronom 1. dan. Kontrolna shema za mladostnike, stare od 12 do 17 let (n = 48), in otroke, stare od 6 mesecev do manj kot 12 let (n = 102), je obsegala placebo 1., 2. in 3. dan v kombinaciji z ondansetronom 1. dan.
EU/1/03/262/001 1 hard capsule EU/1/03/262/002 2 x 1 hard capsule EU/1/03/262/003 5 x 1 hard capsule 
EU/1/03/262/001 1 trda kapsula EU/1/03/262/002 2 x 1 trda kapsula EU/1/03/262/003 5 x 1 trda kapsula
If you or the child gets any side effects, talk to your doctor, pharmacist, or nurse. 
Če vi ali otrok opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Each hard capsule contains 125 mg of aprepitant. 
Ena trda kapsula vsebuje 125 mg aprepitanta.
EMEND 125 mg powder for oral suspension 
EMEND 125 mg prašek za peroralno suspenzijo
It is important that you tell your doctor if you are breast-feeding or are planning to breast-feed before taking this medicine. 
Pomembno je, da pred začetkom jemanja tega zdravila poveste zdravniku, če dojite ali nameravate dojiti.
Psychiatric disorders insomnia uncommon 
Psihiatrične motnje nespečnost občasni
Each hard capsule contains 80 mg of aprepitant. 
Ena trda kapsula vsebuje 80 mg aprepitanta.
Each sachet contains 125 mg of aprepitant. 
Ena vrečka vsebuje 125 mg aprepitanta.
EU/1/03/262/009 1 hard capsule EU/1/03/262/010 6 x 1 hard capsule 
EU/1/03/262/009 1 trda kapsula EU/1/03/262/010 6 x 1 trda kapsula
EMEND 40 mg hard capsules 
EMEND 40 mg trde kapsule
What EMEND looks like and contents of the pack The 165 mg hard capsule is opaque with a light blue cap and a white body with “466” and “165 mg” printed radially in black ink on one side of the body and the Merck logo on the other side. 
165 mg trda kapsula je neprozorna, s pokrovčkom svetlo modre barve in telesom bele barve; na eni strani sta na telo radialno s črnim črnilom natisnjeni oznaki "466" in "165 mg", na drugi strani pa je Merckov logotip.
The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with aprepitant than with standard therapy or in postmarketing use. 
Spodaj so navedeni neželeni učinki, ki so jih v metaanalizi študij HEC in MEC pri aprepitantu opazili pogosteje kot pri standardnem zdravljenju, in neželeni učinki iz obdobja trženja zdravila.
PARTICULARS TO APPEAR ON THE SMALL IMMEDIATE PACKAGING 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
The 80 mg capsules are opaque with a white body and cap with “461” and “80 mg” printed radially in black ink on the body. 
80 mg kapsule so neprozorne; telo je bele barve, pokrovček je bele barve; na telesu kapsule sta radialno s črnim črnilom natisnjeni oznaki "461" in "80 mg".
- If the child gets any side effects, talk to the doctor, pharmacist, or nurse. 
- Če se otroku pojavi kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
(E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, 
(E 463), natrijev lavrilsulfat, želatina, titanov dioksid (E 171), šelak, kalijev hidroksid, črni železov oksid (E 172) in rumeni železov oksid (E 172).
Respiratory, thoracic and mediastinal disorders dyspnoea, wheezing uncommon 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja, sopenje občasni
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with EMEND 165 mg. 
Pri sočasni uporabi z zdravilom EMEND 165 mg je treba upoštevati možne učinke zvišanih plazemskih koncentracij midazolama in drugih benzodiazepinov, ki se presnavljajo s CYP3A4 (alprazolam, triazolam).
Fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3). 
Študije plodnosti niso pokazale neposrednih ali posrednih škodljivih učinkov na parjenje, plodnost, razvoj zarodka/plodu ali število in gibljivost semenčic (glejte poglavje 5.3).
Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction), - euphoria (feeling of extreme happiness), disorientation, - bacterial infection, fungal infection, - severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating, - frequent urination, passing more urine than normal, presence of sugar or blood in urine, - chest discomfort, swelling, change in the manner of walking, - cough, mucus in back of throat, throat irritation, sneezing, sore throat, - eye discharge and itching, - ringing in the ear, - muscle spasms, muscle weakness, - excessive thirst, - slow heartbeat, heart and blood vessel disease, - lowering of white blood cells, low sodium levels in the blood, weight loss. 
napihnjenost, - pogosto uriniranje, izločanje več urina kot običajno, prisotnost sladkorja ali krvi v urinu, - nelagodje v prsnem košu, otekanje, sprememba v načinu hoje, - kašelj, sluz na zadnji steni žrela, draženje žrela, kihanje, vnetje žrela, - izcedek iz očesa in srbenje, - zvonjenje v ušesih, - mišični krči, šibkost mišic, - prekomerna žeja, - počasen srčni utrip, srčno in žilno obolenje, - zmanjšanje števila belih krvnih celic, nizka vrednost natrija v krvi, izguba telesne mase.
EMEND 125 mg hard capsules EMEND 80 mg hard capsules 
EMEND 125 mg trde kapsule EMEND 80 mg trde kapsule
Your child may need blood tests during treatment with EMEND - antibiotics to treat infections - such as rifampicin, clarithromycin, telithromycin - phenytoin - for fits (seizures) - carbamazepine - for depression and epilepsy - midazolam, triazolam, phenobarbital - to produce calmness or help you sleep - St. John's Wort - a herbal medicine for depression - protease inhibitors - for HIV infections - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol) - antifungal medicines such as itraconazole, voriconazole, posaconazole - nefazodone - for depression - corticosteroids - such as dexamethasone and methylprednisolone - medicines for anxiety such as alprazolam - tolbutamide - for diabetes - contraceptive medicines including pills, patches, implants, and some Intrauterine devices 
- antibiotike za zdravljenje okužb - na primer rifampicin, klaritromicin, telitromicin - fenitoin - za zdravljenje epileptičnih krčev (napadov) - karbamazepin - za zdravljenje depresije in epilepsije - midazolam, triazolam, fenobarbital - za pomirjanje in lažje spanje - šentjanževko - rastlinski pripravek za zdravljenje depresije - zaviralce proteaz - za zdravljenje okužbe s HIV - ketokonazol - razen šampona (za zdravljenje Cushingovega sindroma - če v telesu nastaja preveč kortizola) - protiglivna zdravila, na primer itrakonazol, vorikonazol, posakonazol - nefazodon - za zdravljenje depresije - kortikosteroide - na primer deksametazon in metilprednizolon - zdravila proti tesnobnosti na primer alprazolam - tolbutamid - za zdravljenje sladkorne bolezni - kontracepcijska sredstva, vključno s tabletami, obliži, vsadki in nekaterimi materničnimi vložki
If the child gets any side effects, talk to the doctor, pharmacist, or nurse. 
Če se otroku pojavi kateri koli izmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
5 Aluminium blisters each containing one 80 mg capsule. 
Pet aluminijastih pretisnih omotov, ki vsebujejo po eno 80 mg kapsulo.
Before treatment with EMEND, tell your doctor if you have liver disease because your liver is important in breaking down the medicine in your body. 
Pred zdravljenjem z zdravilom EMEND obvestite zdravnika, če imate bolezen jeter, ker jetra sodelujejo pri presnovi zdravila v telesu.
Check the EMEND mixture for any clumps or foaming: - If any clumps are present, repeat Step 7 until there are no clumps. 
- Če so prisotne grudice, ponavljajte 7. korak toliko časa, da grudic ne bo več.
EMEND contains sucrose 
Zdravilo EMEND vsebuje saharozo
EMEND 125 mg hard capsule EMEND 80 mg hard capsules Aprepitant 
EMEND 125 mg trde kapsule EMEND 80 mg trde kapsule aprepitant
Aprepitant should be used with caution in these patients (see sections 4.4 and 5.2). 
Podatkov za bolnike z zmerno okvaro jeter je malo, podatkov za bolnike s hudo okvaro jeter pa ni. Aprepitant je treba pri teh bolnikih uporabljati previdno (glejte poglavji 4.4 in 5.2).
The total exposure of orally administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment with EMEND; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller. 
Celokupna izpostavitev peroralno vzetim substratom za CYP3A4 se lahko poveča do približno 3-krat med 3-dnevnim zdravljenjem z zdravilom EMEND.
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in adults receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %). 
Najpogostejši neželeni učinek, o katerem so pri odraslih, ki so prejemali zmerno emetogeno kemoterapijo (MEC - Moderately Emetogenic Chemotherapy), poročali pogosteje pri bolnikih zdravljenih z aprepitantom kot pri standardni terapiji, je bila utrujenost (1,4 % v primerjavi z 0,9 %).
There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. 
Podatkov o uporabi pri bolnikih s hudo okvaro jeter ni.
prior to administration. 
- Navodilo shranite.
5 Aluminium blisters each containing one 40 mg capsule. 
Pet aluminijastih pretisnih omotov, ki vsebujejo po eno 40 mg kapsulo.
In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely during treatment with EMEND and for 14 days following the use of EMEND (see section 4.5). 
Sočasna uporaba z varfarinom (substratom CYP2C9) Pri bolnikih na kroničnem zdravljenju z varfarinom je treba internacionalno normalizirano razmerje (INR) skrbno spremljati med zdravljenjem z zdravilom EMEND in še 14 dni po uporabi zdravila EMEND (glejte poglavje 4.5).
EMEND should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5). 
Zdravilo EMEND je treba uporabljati previdno pri bolnikih, ki sočasno prejemajo zdravilne učinkovine, ki se primarno presnavljajo s CYP3A4 in z ozkim terapevtskim območjem, kot so ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, derivati ergot alkaloidov, fentanil in kinidin (glejte poglavje 4.5).
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %). 
Najpogostejši neželeni učinek, o katerem so pri bolnikih zdravljenih z aprepitantom, ki so prejemali zmerno emetogeno kemoterapijo (MEC - Moderately Emetogenic Chemotherapy), poročali pogosteje kot pri standardni terapiji, je bila utrujenost (1,4 % v primerjavi z 0,9 %).
EU/1/03/262/004 1 hard capsule EU/1/03/262/005 5 x 1 hard capsule 
EU/1/03/262/004 1 trda kapsula EU/1/03/262/005 5 x 1 trda kapsula
The AUC of orally administrated midazolam increased by 1.2-fold when a single dose of 40 mg aprepitant was co-administered with a single oral dose of 2 mg midazolam; this effect was not considered clinically important. 
Pri sočasnem dajanju enkratnega 40 mg odmerka aprepitanta in enkratnega 2 mg peroralnega odmerka midazolama se je AUC peroralno danega midazolama povečal za 1,2-krat.
The most common adverse reaction reported at a greater incidence in patients treated with the 3-day oral aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %). 
Najpogostejši neželeni učinek, o katerem so pri bolnikih, ki so prejemali zmerno emetogeno kemoterapijo (MEC - Moderately Emetogenic Chemotherapy), poročali pogosteje pri bolnikih, ki so bili zdravljeni po 3-dnevni shemi s peroralnim aprepitantom, kot pri bolnikih, ki so bili zdravljeni s standardno terapijo, je bila utrujenost (1,4 % v primerjavi z 0,9 %).
When a single 125 mg dose of EMEND was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilised on chronic warfarin therapy, there was no effect of EMEND on the plasma AUC of R(+) or S(-) warfarin determined on Day 3; however, there was a 34 % decrease in S(-) warfarin (a CYP2C9 substrate) 
Pri zdravih preiskovancih, stabiliziranih na kroničnem zdravljenju z varfarinom, zdravljenje z zdravilom EMEND po shemi enkratni odmerek 125 mg 1. dan ter 80 mg/dan 2. in 3. dan ni vplivalo na plazemsko vrednost AUC R(+) ali S(-) varfarina, izmerjeno 3. dan.
Another or additional non-hormonal form of birth control should be used during treatment with EMEND and for up to 2 months after using EMEND, - pimozide (used to treat psychiatric illnesses), - terfenadine; astemizole (used for hay fever and other allergic conditions), - cisapride (used for treating digestive problems), - medicines containing ergot alkaloid derivatives (used for treating migraines), - rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections), - phenytoin (a medicine used to treat seizures), - carbamazepine (used to treat depression and epilepsy), - midazolam, phenobarbital (medicines used to produce calmness or help you sleep), - St. John's Wort (an herbal preparation used to treat depression), - protease inhibitors (used to treat HIV infections), - nefazodone (used to treat depression), - ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol), - itraconazole, voriconazole, posaconazole (antifungals), - corticosteroids (such as dexamethasone) 
- pimozid (za zdravljenje psihiatričnih bolezni), - terfenadin, astemizol (za zdravljenje senenega nahoda in drugih alergijskih bolezni), - cisaprid (za zdravljenje prebavnih težav), - zdravila, ki vsebujejo derivate ergot alkaloidov (za zdravljenje migrene), - rifampicin, klaritromicin, telitromicin (antibiotiki za zdravljenje okužb), - fenitoin (zdravilo za zdravljenje epileptičnih krčev/napadov), - karbamazepin (za zdravljenje depresije in epilepsije), - midazolam, fenobarbital (zdravili za pomirjanje in lažje spanje), - šentjanževka (rastlinski pripravek za zdravljenje depresije), - zaviralci proteaz (za zdravljenje okužbe s HIV), - nefazodon (za zdravljenje depresije), - ketokonazol - razen šampona (za zdravljenje Cushingovega sindroma - če v telesu nastaja preveč kortizola), - itrakonazol, vorikonazol, posakonazol (za zdravljenje glivičnih okužb), - kortikosteroidi (kot je deksametazon).
EMEND should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5). 
Zdravilo EMEND je treba uporabljati previdno pri bolnikih, ki sočasno prejemajo peroralne zdravilne učinkovine, ki se primarno presnavljajo s CYP3A4 in z ozkim terapevtskim območjem, kot so ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, derivati ergot alkaloidov, fentanil in kinidin (glejte poglavje 4.5).
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with EMEND (125 mg/80 mg). 
Pri sočasni uporabi z zdravilom EMEND (125 mg/80 mg) je treba upoštevati možne učinke zvišanih plazemskih koncentracij midazolama in drugih benzodiazepinov, ki se presnavljajo s CYP3A4 (alprazolam, triazolam).
ALT increased common 
Preiskave zvišanje vrednosti ALT
EU/1/03/262/007 1 hard capsule EU/1/03/262/008 5 x 1 hard capsule 
EU/1/03/262/007 1 trda kapsula EU/1/03/262/008 5 x 1 trda kapsula
Refer to the powder for oral suspension SmPC for appropriate dosing in infants, toddlers and children aged 6 months to less than 12 years. 
EMEND 125 mg prašek za peroralno suspenzijo aprepitant za otroke, stare od 6 mesecev do manj kot 12 let
The oral suspension can be kept at room temperature (not above 30 oC) for up to 3 hours, prior to administration. 
Peroralno suspenzijo se lahko hrani na sobni temperaturi (do 30 °C) do 3 ure pred uporabo.
EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3. 
125 mg 1. dan in 40 mg peroralno 2. in 3. dan povečalo vrednost AUC metilprednizolona, ki je substrat CYP3A4, in sicer za 1,3-krat 1. dan ter za 2,5-krat 3. dan.
• Use the 5 mL oral dispenser to measure 4.6 mL of water, which is added into the mixing cup. 
• Za odmero 4,6 ml vode, ki jo boste dali v čašo za mešanje, uporabite 5-ml odmernik.
Do not give the child more of this medicine than the doctor recommends. 
Če ste dali večji odmerek zdravila EMEND, kot bi smeli Otroku ne smete dati več zdravila, kot je naročil zdravnik.
500-1,500 mg/m 2 and doxorubicin (< 60 mg/m 2) or epirubicin (< 100 mg/m 2), aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with standard therapy (placebo plus ondansetron 8 mg orally (twice on Day 1, and every 12 hours on Days 2 and 3) plus dexamethasone 20 mg orally on Day 1). 
V randomizirani, dvojno slepi študiji, ki je skupaj zajela 866 odraslih bolnikov (864 žensk, 2 moška), ki so dobivali kemoterapijo s ciklofosfamidom 750-1500 mg/m2 ali ciklofosfamidom 5001500 mg/m in doksorubicinom ( 60 mg/m2) ali epirubicinom ( 100 mg/m2), so primerjali aprepitant v kombinaciji z ondansetronom/deksametazonom (glejte poglavje 4.2) ter standardno terapijo (placebo in ondansetron 8 mg peroralno (dvakrat 1. dan ter na 12 ur 2. in 3. dan) ter deksametazon 20 mg peroralno 1. dan).
EMEND 125 mg powder for oral suspension Aprepitant 
EMEND 125 mg prašek za peroralno suspenzijo aprepitant peroralna uporaba